On 12 May 2026 the European Parliament and the Council reached a provisional agreement on the Critical Medicines Act. EMA welcomed it as a step towards a more resilient and secure supply of critical medicines in the EU.
What EMA highlighted
EMA describes the Act as pairing regulatory tools with targeted industrial policy to strengthen preparedness and manufacturing capacity. It builds on EMA’s extended crisis mandate and complements the revised pharmaceutical legislation. EMA also notes that the Act aims to improve access to medicines of common interest that may not be available in some Member States, such as rare disease medicines.
Vulnerability assessments
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products will carry out supply chain vulnerability assessments to inform policy. It is already assessing a first set of medicines from the Union list of critical medicines, which covers more than 200 active substances.
Quality innovation and monitoring
- Quality Innovation Expert Group. The Act recognises and strengthens the group EMA established in 2022 to support advanced manufacturing approaches.
- Shortage monitoring. The European Shortages Monitoring Platform is being expanded.
- State aid and joint procurement. These proposals lie outside EMA’s remit but form part of the wider package.
What is still open
EMA’s statement gives no timetable for formal adoption or application, so companies should follow the legislative steps and prepare on a no-regrets basis: map dependency on critical active substances, know single-source exposure and understand how procurement criteria may reward diversified supply.
How PQRA helps
PQRA assists manufacturers and marketing authorisation holders with supply chain risk mapping, regulatory strategy for site and source changes, and alignment of quality and regulatory plans with emerging resilience requirements.


No responses yet